REG - Aptamer Group PLC - AGM Statement

AptamerAnnouncement

15/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231215:nRSO9073Wa&default-theme=true

RNS Number : 9073W  Aptamer Group PLC  15 December 2023

15 December 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Annual General Meeting Statement

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, will hold its Annual
General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group plc,
Windmill House, Innovation Way, York, YO10 5BR.

 

Since the Group was recapitalised in August 2023, it has made significant
technical and commercial progress. This includes a reduction of the cost
base, streamlining of the production processes for increased production
capacity and a reduction of material requirements from customers. The Group
has continued to build and convert the commercial pipeline, including the
recent announcement of a partnership with a genetic medicines company for
Optimer development to support targeted delivery of new medicines. No new
material information will be provided.

 

The results of the AGM will be announced to the London Stock Exchange and
placed on the Group's website, in the usual way, as soon as practicable after
the conclusion of the AGM.

 

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMTIBMTMTMBTRJ